Med Page Today
NOVEMBER 18, 2024
(MedPage Today) -- More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated. Among 25,531 participants in the National Health and Nutrition Examination Survey (NHANES) from 2015 to.
DAIC
NOVEMBER 18, 2024
tim.hodson Mon, 11/18/2024 - 10:55 Nov. 16, 2024 Anthos Therapeutics, Inc.recently presented new data at the American Heart Association (AHA) Scientific Sessions from its AZALEA-TIMI 71 study that demonstrated the novel factor XI inhibitor abelacimab led to consistent and substantial reductions in bleeding for patients on or off antiplatelet (APT) therapy, as compared to rivaroxaban.
American Heart News - Heart News
NOVEMBER 18, 2024
Research Highlights: The oral medication muvalaplin may safely lower high levels of lipoprotein(a), also known as Lp(a), an independent, inherited risk factor for cardiovascular disease. Muvalaplin is a small molecule inhibitor that prevents the.
Med Page Today
NOVEMBER 18, 2024
(MedPage Today) -- CHICAGO -- Electronic nudges increased uptake of flu vaccines among patients with a history of acute myocardial infarction (MI), results from three Danish randomized trials showed. Among over 2 million patients, a letter explaining.
HCPLive
NOVEMBER 18, 2024
Panelists discuss the immune system dysregulation underlying IgA nephropathy and highlight how this mechanism differs from those seen in other glomerular diseases.
Medical Xpress - Cardiology
NOVEMBER 18, 2024
University of California, San Diego-led research suggests that long-term variability in blood pressure is associated with accelerated worsening of peripheral vision due to the progression of glaucoma.
American Heart News - Heart News
NOVEMBER 18, 2024
Research Highlights: A study testing a new nasal spray form of the medication bumetanide, a commonly prescribed diuretic, was found to be as safe and well-tolerated (meaning with no significant nasal irritation) in healthy adults in comparison to the.
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
Med Page Today
NOVEMBER 18, 2024
(MedPage Today) -- WASHINGTON -- Patients taking Janus kinase (JAK) inhibitors for rheumatoid arthritis (RA) may not have to worry so much about increased cardiovascular risk -- if they're taking statins, research presented here suggested.
Medical Xpress - Cardiology
NOVEMBER 18, 2024
There is a dose-response relationship between rising outdoor temperatures and increased atrial fibrillation (AF) events, according to a study presented at the American Heart Association Scientific Sessions 2024, held from Nov. 16 to 18 in Chicago.
Med Page Today
NOVEMBER 18, 2024
(MedPage Today) -- CHICAGO -- Secondhand permanent pacemaker use in poorer countries, following thorough cleaning and repackaging, has not resulted in patient harm so far, according to the My Heart Your Heart trialists. In patients who could.
Nature Reviews - Cardiology
NOVEMBER 18, 2024
Nature Reviews Cardiology, Published online: 19 November 2024; doi:10.1038/s41569-024-01105-y Large language models represent a transformative leap in artificial intelligence and natural language processing, offering exciting potential across cardiology, from clinical care to education and research. However, several crucial challenges limit the practical implementation of large language models in cardiology.
Clinical Trial Results
NOVEMBER 18, 2024
Disclosures: TBD
HCPLive
NOVEMBER 18, 2024
Zhang explains the safety of different FDA-approved alcohol use disorder drugs in patients with alcohol-associated liver disease.
Becker's Hospital Review - Cardiology
NOVEMBER 18, 2024
Between 2008 and 2019, the share of cardiologists practicing in a hospital, as opposed to an independent practice, increased from 26% to 63%, according to a study published Nov. 15 in the Journal of the American College of Cardiology.
American College of Cardiology
NOVEMBER 18, 2024
What is the incremental benefit in patients with heart failure and preserved ejection fraction (HFpEF) of glucagon-like peptide-1 receptor agonists (GLP-1 RA) combined with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM) and body mass index (BMI) ≥27?
Science Daily - Heart Disease
NOVEMBER 18, 2024
Salk scientists have tracked the flow of trans fats using mouse models to describe the molecular mechanisms that cause trans fats to promote atherosclerotic cardiovascular disease (ASCVD), explaining how industrially produced trans-unsaturated fatty acids in our food significantly promote ASCVD and encouraging lawmakers to impose regulations on the use of these fats in food.
American College of Cardiology
NOVEMBER 18, 2024
Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to new research published in JACC and simultaneously presented at AHA 2024.
Medical Xpress - Cardiology
NOVEMBER 18, 2024
Polygenic risk scores (PRSs) are a cutting-edge tool in genetics, combining information from genetic markers across the genome to estimate a person's risk of developing certain diseases, such as coronary artery disease (CAD). By analyzing a person's DNA, PRSs offer insights into an individual's genetic predisposition for conditions like heart disease, potentially informing a more personalized approach to health care.
American College of Cardiology
NOVEMBER 18, 2024
Zerlasiran, a short-interfering RNA, was well-tolerated and reduced time-averaged lipoprotein(a) [Lp(a)] concentration by more than 80% during 36 weeks of treatment in patients with atherosclerotic cardiovascular disease (ASCVD).
HCPLive
NOVEMBER 18, 2024
Over one-third of participants had had inadequate responses or intolerance to at least 3 prior b/tsDMARDs.
Science Daily - Heart Disease
NOVEMBER 18, 2024
While exercise is generally beneficial for a person's overall health, physical activities may increase the risk of adverse cardiovascular disease events in certain susceptible individuals. However, cardiologists say that the benefits outweigh the risks. Findings from new data reviews detail the risks associated with various types of sport and leisure activities.
HCPLive
NOVEMBER 18, 2024
In this interview, Han highlighted new information included in the GOLD 2025 Report regarding utilization of dupilumab and ensifentrine for certain patients with COPD.
American College of Cardiology
NOVEMBER 18, 2024
The goal of the KRAKEN trial was to evaluate muvalaplin compared with placebo among patients with high cardiovascular risk and elevated lipoprotein(a).
HCPLive
NOVEMBER 18, 2024
However, fewer patients experienced flares in the tofacitinib group than in the placebo group, among other positive findings.
Cardiovascular Diabetology
NOVEMBER 18, 2024
Individuals with type 1 diabetes are at increased risk of accelerated atherosclerosis, causing coronary artery disease (CAD). The underlying mechanisms remain unclear, but new theories proposed are damage of g.
HCPLive
NOVEMBER 18, 2024
Gossec discussed findings from the PsABIOnd study presented at the 2024 ACR Convergence.
Becker's Hospital Review - Cardiology
NOVEMBER 18, 2024
The GLP-1 tirzepatide, the active ingredient in Eli Lilly's Mounjaro, was found to reduce the risk of heart failure by 46% among individuals with obesity, according to a study published Nov. 16 in The New England Journal of Medicine and presented at the American Heart Association's annual Scientific Sessions.
HCPLive
NOVEMBER 18, 2024
In these updates and new sections, the 2025 GOLD report included highlighted climate change, cardiovascular risk, and pulmonary hypertension.
American Heart News - Heart News
NOVEMBER 18, 2024
Research Highlights: A clinical trial with adults who have atrial fibrillation (AFib) and an implanted heart device found similar improvements to the amount of time they experienced arrhythmia regardless of whether they received standard care.
HCPLive
NOVEMBER 18, 2024
Zerlasiran reduced Lp(a) by over 90% at 60 weeks with consistent efficacy and no serious drug-related adverse events, supporting its phase 3 trial progression.
American Heart News - Heart News
NOVEMBER 18, 2024
Research Highlights: A widely used heart failure medication called sacubitril/valsartan was associated with a lower risk of heart damage compared to placebo among high-risk cancer patients being treated with anthracycline chemotherapy agents. The risk.
HCPLive
NOVEMBER 18, 2024
HCPLive spoke with Lat at NASPGHAN 2024 about how for communities with high H. pylori prevalence, it is best to test for H. pylori before a colonoscopy.
Science Daily - Heart Disease
NOVEMBER 18, 2024
A commonly prescribed medication for heart failure was linked to a lower risk of heart damage, or cardiotoxicity, among high-risk cancer patients undergoing chemotherapy treatment using anthracyclines, according to recent research.
American College of Cardiology
NOVEMBER 18, 2024
Sacubitril/valsartan was associated with a lower risk cardiotoxicity compared with placebo among high-risk cancer patients being treated with anthracycline (ATN) chemotherapy agents.
Clinical Trial Results
NOVEMBER 18, 2024
AHA BROOKLYN nov17 Download Disclosures: TBD
American College of Cardiology
NOVEMBER 18, 2024
In this episode, Drs. Newton Wiggins, Stanley Lui, and Sandra Lewis discuss the importance of finances and how aligning your financial situation with your values can foster career flexibility and improve clinician well-being.
Cardiovascular Diabetology
NOVEMBER 18, 2024
The article by Wang et al. titled “Exploring the mortality and cardiovascular outcomes with SGLT-2 inhibitors in patients with T2DM at dialysis commencement: a health global federated network analysis” demonst.
Expert insights. Personalized for you.
121 
Let's personalize your content